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We describe genomic ﬁndings in a case of CLL with del(17p13.1) by FISH, in which SNP array analysis
revealed chromothripsis, a phenomenon by which regions of the cancer genome are shattered and
recombined to generate frequent oscillations between two DNA copy number states. The ﬁndings
illustrate the value of SNP arrays for precise whole genome proﬁling in CLL and for the detection of
alterations that would be overlooked with a standard FISH panel. This second report of chromothripsis
in CLL indicates that this phenomenon is a recurrent change in this disease.
& 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Because lymphocytes of chronic lymphocytic leukemia (CLL)
patients often fail to divide sufﬁciently in vitro, ﬂuorescence
in situ hybridization (FISH) probes have become a staple in the
analysis of chromosomal aberrations in CLL (reviewed in Ref. 1).
In a groundbreaking study, a FISH probe panel was used to
classify CLL patients into one of ﬁve prognostic groups, with the
poorest prognosis seen in patients with deletion of 17p13.1 (site
of TP53), followed by loss of 11q22.3 (ATM), trisomy 12 and
normal FISH results, whereas patients with del(13q14) as the only
alteration had the most favorable prognosis.2
Although FISH analysis is now widely used for the cytogenetic
assessment of CLL, other approaches such as oligonucleotide-based
array comparative genomic hybridization and single nucleotide
polymorphism (SNP) gene chips show comparable results, but also
assess all chromosomal regions rather than the current standard
clinical practice of identifying alterations with probes targeting
only 4–5 chromosomal sites.3,4 The high-resolution gene copy
number analysis afforded by DNA arrays provides greater precision
in demarcating boundaries of individual genomic imbalances and
uncovers alterations overlooked by FISH analysis. In this report, we
describe cytogenetic ﬁndings in a CLL case with del(17p13.1) by
FISH in which SNP arrays detected profound genomic upheaval due
to chromothripsis, a phenomenon by which a speciﬁc region(s) ofY-NC-ND license.the cancer genome is shattered into pieces and then recombined
via a single devastating event, generating frequent oscillations
between two DNA copy number states, that may lead to malignant
transformation.52. Materials and methods
Karyotypic analysis was performed on a blood sample cultured
for 24 h. FISH analysis was performed using Abbott’s Vysis CLL
FISH Probe Kit. DNA copy number and allele analysis were
performed as described in detail elsewhere.6 Brieﬂy, total geno-
mic DNA from blood was Nsp-digested, ligated with an adaptor
complimentary to PCR primer, PCR ampliﬁed, puriﬁed, fragmen-
ted, biotin labeled, and hybridized to an Affymetrix CytoScan HD
array, according to the manufacturer’s protocol. The hybridized
array was washed and then scanned with a GeneChip Scanner
3000 7G prior to data analysis.3. Results
Karyotyping revealed chromosomal abnormalities in 19 of 20
metaphase spreads examined. All abnormal metaphases had a
del(14)(q22), and 17 metaphases were interpreted to contain a three
way translocation, t(2;5;7)(q31;q21;q11.2) and loss of all or part of
chromosome 6. FISH analysis showed loss of one copy of TP53 in 95 of
150 nuclei examined and loss of MYB (at 6q23.3) in 10 of 150 nuclei.
No abnormalities were detected for ATM (11q22.3), D12Z3 (12cen),
D13S319 (13q14.2-q14.3), or LAMP1 (13q34).
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Fig. 1. Depiction of DNA copy number and allele peaks in the abnormal chromo-
somes identiﬁed in blood sample from CLL patient. For each chromosome shown,
the y axis depicts DNA copy number (Upper) and allele peaks (Lower). Allele peak
panels normally show three distinct ‘‘bands,’’ representing all homozygous (Top
and Bottom bands) and heterozygous (Middle band) allele calls. Note multiple
oscillations between two DNA copy number states in chromosomes 2, 5, 6 and 7,
indicative of chromothripsis. Numerous discontinuous deletions are indicated by
blue arrows, with allele peak panels showing only two bands (loss of hetero-
zygosity) at chromosomal segments corresponding to each deletion. In addition to
these focal deletions, larger single deletions can be seen in chromosome arms 14q
and 17p, the latter encompassing the TP53 locus (green arrow). (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
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pattern, including chromothripsis involving several chromo-
somes, numerous tiny focal deletions in other chromosomes,
and larger deletions in 14q and 17p (Fig. 1). The del(17p) included
TP53, consistent with the FISH analysis. As is typical of chromo-
thripsis, multiple oscillations between two DNA copy number
states were observed. In this case, the changes were almost
exclusively ﬂuctuations between one and two copies, resulting
in discontinuous deletions of numerous segments in chromo-
somes 2, 5, 6 and 7.4. Discussion
While the DNA copy number data were in agreement with the
FISH ﬁndings, the genome-wide DNA copy number analysis also
uncovered many other abnormalities indicative of chaotic geno-
mic disruption. Chromothripsis is thought to occur during a single
cellular catastrophe and may occur in at least 2%–3% of all
cancers, across many subtypes.5 Interestingly, the very ﬁrst
reported evidence of chromothripsis was found via a genome-
wide sequencing screen of 10 CLL patients, one (a previously
untreated 62-yr-old woman) showing massive rearrangement of
chromosome arm 4q and focal alterations of chromosomes 1, 12,
and 15.5 The copy number changes in 4q alternated between
1 and 2, with regions of copy number 1 showing loss of hetero-
zygosity (LOH), whereas regions of copy number 2 retained
heterozygosity. The whole genome sequencing revealed that the
many discontinuous regions of copy number 1 in 4q were not
caused by simple deletions but instead were the result of a series
of complex rearrangements spanning 4q. In that same report,
subsequent study uncovered a second CLL patient with losses of
single copies of CDKN2A and miR-15a/16-a due to a cluster ofinterchromosomal rearrangements involving chromosomes 4, 9,
and 13. In our patient, the discontinuous regions of LOH in
chromosomes 2, 5, 6 and 7 are also separated by regions retaining
heterozygosity (Fig. 1). Notably, the clinical course in the initial
CLL patient reported by Stephens et al.5 showed rapid deteriora-
tion and quickly relapsed. Sequence analysis of a relapse speci-
men collected 31 months after diagnosis revealed no new
genomic rearrangements, suggesting that the process generating
this complex genomic remodeling had occurred before the patient
was diagnosed and was not indicative of further genomic
instability.
As noted above, while FISH evidence for a deletion of chromo-
some 17p13.1 (TP53) is generally associated with a poor prognosis,
CLL patients with del(17p13.1) exhibit clinical heterogeneity.
Some TP53-deﬁcient CLL patients have a relatively indolent
course. One reason for such heterogeneity may be that not all
cases with loss of one copy of TP53 have a mutation in the
remaining allele. Thus, there is insufﬁcient evidence for rigid
therapeutic recommendations to be made based on deletion of
17p alone, although survival may be predicted using other risk
factors for progressive disease including the presence of unmu-
tated immunoglobulin heavy-chain variable region genes (IGHV).7
As in other hematological malignancies, the genetic proﬁle of
CLL may evolve during the disease course. For example, while
del(17p13.1) is uncommon at the time of diagnosis (5%–10%), it is
observed in about 45% of patients with relapsed or refractory
CLL.7 In del(17p13.1) CLL cases, clonal evolution with acquisition
of other genomic imbalances is associated with unmutated IGVH,
resistance to therapy, and short survival.8 As array-based DNA
copy number analysis becomes more widely used in the clinical
setting, it will be important to determine if chromothripsis
represents yet another risk factor of progressive disease, as we
predict. Unfortunately, we do not know whether or not the
disease course was rapid in our CLL patient, because the DNA
was from a de-identiﬁed sample that was used for a validation
study of a DNA copy number assay.
The deletion of 14q seen in our patient included the IGH locus at
14q32.33. This is noteworthy, because loss of 14q has been reported
as a recurrent aberration acquired during the natural history of CLL.9
The acquisition of a del(14) may thus be indicative of CLL in
transformation. In a study of a large German cohort, del(14q) was
found in 2% of newly diagnosed CLLs, and these patients typically
required more immediate therapy.10 The investigators used a panel
of 14q probes to determine that the del(14) was usually interstitial
and heterogeneous in size, with a breakpoint cluster at the cen-
tromeric site in 14q24.1; in most cases the breakpoint at the
telomeric site was within the IGH locus while 25% showed a
deletion of the entire IGH locus, as was the case in our patient.
In conclusion, this report illustrates the value of SNP arrays for
precise whole genome proﬁling of chromosomal alterations in CLL
and the detection of complex alterations that would be overlooked
with a standard FISH panel. The identiﬁcation of this third case of
chromothripsis in CLL indicates that this phenomenon is a recurrent
change in this disease, and future studies may determine if its
occurrence is associated with distinctive clinical features.Conﬂict of interest
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